Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

Jan H. Beumer; Edward Chu; Carmen Allegra; Yusuke Tanigawara; Gerard Milano; Robert Diasio; Tae Won Kim; Ron H. Mathijssen; Li Zhang; Dirk Arnold; Katsuki Muneoka; Narikazu Boku; Markus Joerger

doi:10.1002/cpt.1124

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

Jan H. Beumer^*
, Edward Chu
, Carmen Allegra
, Yusuke Tanigawara
, Gerard Milano
, Robert Diasio
, Tae Won Kim
, Ron H. Mathijssen
, Li Zhang
, Dirk Arnold
, Katsuki Muneoka
, Narikazu Boku
, Markus Joerger

^*Corresponding author for this work

Medical Oncology

University of Pittsburgh Cancer Institute
University of Pittsburgh
University of Pittsburgh School of Medicine
University of Florida
Keio University School of Medicine
Centre Antoine Lacassagne
Mayo Clinic Rochester, MN
Mayo Clinic College of Medicine and Science
University of Ulsan College of Medicine
Sun Yat-Sen University
Asklepios Klinik St. Georg
Niitsu Medical Center Hospital
National Cancer Center Japan
Cantonal Hospital St. Gallen

Research output: Contribution to journal › Article › Academic › peer-review

114 Citations (Scopus)

Abstract

5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.

Original language	English
Pages (from-to)	598-613
Number of pages	16
Journal	Clinical Pharmacology & Therapeutics
Volume	105
Issue number	3
DOIs	https://doi.org/10.1002/cpt.1124
Publication status	Published - Mar 2019

Bibliographical note

Funding Information:
Supported in part by grant P30-CA47904 from the National Cancer Institute, National Institutes of Health (NCI-NIH). The content of this position paper and its main conclusions was presented to, and endorsed by, the Therapeutic Drug Monitoring (TDM) in Oncology Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) at the 15th annual meeting in Kyoto, Japan, 2017, and the main conclusions were presented at the IATDMCT 2017 annual meeting. We thank Dr. Salvatore Salamone and Dr. William Clarke for valuable contributions and insights provided to the TDM in Oncology Scientific Committee and to our 5-FU working group. This working group was charged by the TDM in Oncology Scientific Committee of the IATDMCT.

Funding Information:
Supported in part by grant P30-CA47904 from the National Cancer Institute, National Institutes of Health (NCI-NIH).

Publisher Copyright:
© 2018 American Society for Clinical Pharmacology and Therapeutics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC MM-03-86-08

Access to Document

10.1002/cpt.1124

http://hdl.handle.net/1765/110373

Cite this

Beumer, J. H., Chu, E., Allegra, C., Tanigawara, Y., Milano, G., Diasio, R., Kim, T. W., Mathijssen, R. H., Zhang, L., Arnold, D., Muneoka, K., Boku, N., & Joerger, M. (2019). Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. Clinical Pharmacology & Therapeutics, 105(3), 598-613. https://doi.org/10.1002/cpt.1124

@article{b0eb975b5596467ba36b07834cd3250e,

title = "Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy",

abstract = "5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.",

author = "Beumer, \{Jan H.\} and Edward Chu and Carmen Allegra and Yusuke Tanigawara and Gerard Milano and Robert Diasio and Kim, \{Tae Won\} and Mathijssen, \{Ron H.\} and Li Zhang and Dirk Arnold and Katsuki Muneoka and Narikazu Boku and Markus Joerger",

note = "Funding Information: Supported in part by grant P30-CA47904 from the National Cancer Institute, National Institutes of Health (NCI-NIH). The content of this position paper and its main conclusions was presented to, and endorsed by, the Therapeutic Drug Monitoring (TDM) in Oncology Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) at the 15th annual meeting in Kyoto, Japan, 2017, and the main conclusions were presented at the IATDMCT 2017 annual meeting. We thank Dr. Salvatore Salamone and Dr. William Clarke for valuable contributions and insights provided to the TDM in Oncology Scientific Committee and to our 5-FU working group. This working group was charged by the TDM in Oncology Scientific Committee of the IATDMCT. Funding Information: Supported in part by grant P30-CA47904 from the National Cancer Institute, National Institutes of Health (NCI-NIH). Publisher Copyright: {\textcopyright} 2018 American Society for Clinical Pharmacology and Therapeutics",

year = "2019",

month = mar,

doi = "10.1002/cpt.1124",

language = "English",

volume = "105",

pages = "598--613",

journal = "Clinical Pharmacology \& Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "3",

}

Beumer, JH, Chu, E, Allegra, C, Tanigawara, Y, Milano, G, Diasio, R, Kim, TW, Mathijssen, RH, Zhang, L, Arnold, D, Muneoka, K, Boku, N & Joerger, M 2019, 'Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy', Clinical Pharmacology & Therapeutics, vol. 105, no. 3, pp. 598-613. https://doi.org/10.1002/cpt.1124

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. / Beumer, Jan H.; Chu, Edward; Allegra, Carmen et al.
In: Clinical Pharmacology & Therapeutics, Vol. 105, No. 3, 03.2019, p. 598-613.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Therapeutic Drug Monitoring in Oncology

T2 - International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

AU - Beumer, Jan H.

AU - Chu, Edward

AU - Allegra, Carmen

AU - Tanigawara, Yusuke

AU - Milano, Gerard

AU - Diasio, Robert

AU - Kim, Tae Won

AU - Mathijssen, Ron H.

AU - Zhang, Li

AU - Arnold, Dirk

AU - Muneoka, Katsuki

AU - Boku, Narikazu

AU - Joerger, Markus

N1 - Funding Information: Supported in part by grant P30-CA47904 from the National Cancer Institute, National Institutes of Health (NCI-NIH). The content of this position paper and its main conclusions was presented to, and endorsed by, the Therapeutic Drug Monitoring (TDM) in Oncology Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) at the 15th annual meeting in Kyoto, Japan, 2017, and the main conclusions were presented at the IATDMCT 2017 annual meeting. We thank Dr. Salvatore Salamone and Dr. William Clarke for valuable contributions and insights provided to the TDM in Oncology Scientific Committee and to our 5-FU working group. This working group was charged by the TDM in Oncology Scientific Committee of the IATDMCT. Funding Information: Supported in part by grant P30-CA47904 from the National Cancer Institute, National Institutes of Health (NCI-NIH). Publisher Copyright: © 2018 American Society for Clinical Pharmacology and Therapeutics

PY - 2019/3

Y1 - 2019/3

N2 - 5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.

AB - 5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.

UR - https://www.scopus.com/pages/publications/85053435195

U2 - 10.1002/cpt.1124

DO - 10.1002/cpt.1124

M3 - Article

C2 - 29923599

SN - 0009-9236

VL - 105

SP - 598

EP - 613

JO - Clinical Pharmacology & Therapeutics

JF - Clinical Pharmacology & Therapeutics

IS - 3

ER -

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

Abstract

Bibliographical note

UN SDGs

Research programs

Access to Document

Other files and links

Fingerprint

Cite this